Starpharma Holdings Limited · ASX:SPL
Starpharma — Merger or Acquisition (September 2025)
8 slides from Starpharma's merger presentation, Sep 22, 2025
Slide 1: Starpharma Announces Collaboration and License Agreement with Genentech
ASX: SPL US OTC: SPHRY Starpharma Announces Collaboration and License Agreement with Genentech Shareholder Presentation 22 September 2025
Slide 2: Executive Summary
Executive Summary • Starpharma has signed a collaboration and license agreement with Genentech, a member of the Roche Group. • Starpharma will employ its proprietary DEP® platform technology to develop dendrimer- drug conjugates that incorporate Genentech medicines for certain oncology targets. • St
Slide 3: About Starpharma
About Starpharma Starpharma is an Australian biotechnology company with over 20 years of experience in advancing dendrimer technology from the lab to the patient Clinically validated DEP® Leadership in dendrimer science platform technology and drug development More than 350 patients treated with DEP
Slide 4: About Genentech
About Genentech Considered the founder of the biotech industry and now a member of the Roche Group, Genentech has been delivering on the promise of biotechnology for nearly 50 years Pioneering pharmaceutical A community of changemakers innovation Discovered the first targeted antibody for Nearly 50
Slide 5: Collaboration Overview
Collaboration Overview Starpharma will employ its proprietary DEP® platform technology to develop dendrimer-drug conjugates that incorporate Genentech medicines for certain oncology targets. Genentech has an exclusive worldwide license under Starpharma’s IP to commercialize products resulting from t
Slide 6: Financial Terms
Financial Terms Upfront payment USD $5.5 million (~AUD $8.3 million) Success-based milestones Up to USD $564 million (~AUD $855 million) Starpharma is also eligible for tiered royalties on global net sales of products resulting from the collaboration.
Slide 7: Strategic Significance for Starpharma
Strategic Significance for Starpharma Recognises the potential of Starpharma’s dendrimer technology in drug delivery innovation Demonstrates the opportunities presented by research partnerships Marks important progress against our strategic plan
Slide 8: Thank you.
Thank you. Investor Hub Corporate Office investors.starpharma.com 4 – 6 Southampton Crescent Abbotsford, Victoria 3067 Australia
Starpharma Holdings — Merger or Acquisition (September 2025) on 6ix